Owkin Integrating Human and Artificial Intelligence for Better Drugs and Diagnostics

What is Owkin?

Owkin is an AI biotech company focused on improving the understanding of complex biology through the integration of human and artificial intelligence. The company aims to deliver better drugs and diagnostics at scale.

Owkin differentiates itself by focusing on improving the fundamental understanding of disease mechanics through data, biology and AI. This includes access to multimodal data via a network of leading academic partners, leveraging privacy-enhancing technologies, and applying cutting-edge AI, including large language models (LLMs) and foundation models (FMs). The company validates its AI models with the help of medical experts.

Features

Multimodal Patient Data: Access to a network of leading academic partners and medical experts for world-class patient data.
Federated Research Network: Collaboration with top academic centers using privacy-enhancing technologies.
AI-Biomarker Discovery: Application of AI to multimodal data to subtype patients and identify novel biomarkers.
AI Drug Discovery: Use of AI to identify biomarkers, match patient subgroups with targets, and match drugs with new indications.
AI Drug Development: Combination of machine learning, patient data, and innovative modalities to increase clinical trial success.
AI Diagnostics: Development of AI tools to pre-screen for biomarkers and predict patient outcomes.

Use Cases

Identifying new therapeutic targets for drug development.
Accelerating and de-risking clinical trials through AI-powered analysis.
Developing AI-driven diagnostic tools for precision medicine.
Optimizing patient stratification for clinical trials.
Predicting patient outcomes and treatment responses.
Pre-screening patients for biomarker presence.
Understanding complex biological mechanisms of diseases.

FAQs

What makes Owkin different?

Owkin is differentiated by a focus on improving our fundamental understanding of disease mechanics through data, biology and AI.